$ABBV

AbbVie has shown consistent revenue growth, supported by a robust pipeline of treatments and a strong market presence. While the company’s blockbuster drug Humira (adalimumab) has been a cash cow for many years, its revenue generation power remains substantial, even as biosimilars begin to challenge its dominance.